24/7 Market News Snapshot 20 March, 2025 – ARS Pharmaceuticals, Inc. Common Stock (NASDAQ:SPRY)
DENVER, Colo., 20 March, 2025 (247marketnews.com) – (NASDAQ:SPRY) are discussed in this article.
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) is experiencing significant momentum, with its stock price rising from a previous close of $11.650 to $14.159 today, marking an impressive increase of 21.54%. The heightened trading activity, with a volume of 2.09 million shares, reflects strong investor confidence and market enthusiasm for the biopharmaceutical sector, particularly following the launch of its innovative product, neffy® (epinephrine nasal spray).
Neffy, designed for the emergency treatment of Type I allergic reactions, including anaphylaxis, was commercially launched in late September 2024. This groundbreaking formulation is critical for individuals, especially children, at risk of severe allergic reactions. Since its release, neffy has generated $7.3 million in U.S. net product revenue, and the recent FDA approval for its use in children ages four and older adds further significance by providing crucial access to approximately 2 million school-aged children susceptible to life-threatening allergies.
Richard Lowenthal, Co-Founder, President, and CEO of ARS Pharma, emphasized the company’s dedication to empowering patients and caregivers, citing a robust financial foundation with $314 million in cash and investments, enabling a strong commercialization push in 2025. ARS reported total revenue of $89.1 million for the full year 2024, bolstered by key collaboration agreements that enhance its market presence.
To ensure widespread adoption, ARS Pharma is actively engaging around 9,000 healthcare providers and has secured favorable payer coverage. A comprehensive marketing initiative is scheduled to launch in May 2025, strategically timed to align with heightened epinephrine prescribing seasons. Coupled with plans for pivotal studies and potential international market expansion, ARS Pharma is strategically positioned for continued growth and transformative impacts in allergy treatment.
Related news for (SPRY)
- ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray)
- ARS Pharmaceuticals’ neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms
- ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians
- MoBot alert highlights: NASDAQ: PSTV, NASDAQ: AEVA, NASDAQ: TDTH, NASDAQ: SPRY, NASDAQ: ADTX (03/20/25 09:00 AM)